Skip to main content

Table 2 Pharmacokinetics of caspofungin during continuous venovenous hemodiafiltration in 12 patients

From: Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients

 

AUC0-24 (mg h/L)

 

Patient

Arterial

Venous

Difference venous to arterial (%)

Vd (L)

Cl (L/h)

Cmax (mg/L)

Ctrough (mg/L)

t½ (h)

1

140.0

180.0

29

14.1

0.356

12.5

3.47

27.4

2

88.3

106.0

20

17.1

0.567

7.8

2.1

21.0

3

124.0

152.0

23

10.9

0.402

8.8

3.1

18.8

4

65.4

77.4

18

26.8

0.765

6.9

1.3

24.3

5

68.0

90.0

32

17.5

0.735

4.8

1.5

16.5

6

102.0

107.0

5

13.6

0.683

10.7

2.5

13.8

7

65.6

78.8

20

15.0

0.762

8.3

1.6

13.6

8

100.0

113.0

13

13.9

0.499

9.5

2.7

19.3

9

102.0

127.0

25

14.1

0.685

9.2

2.3

14.3

10

121.0

142.0

17

12.5

0.578

12.6

2.9

15.0

11

190.0

224.0

18

13.9

0.368

11.5

4.0

26.2

12

60.1

74.5

24

27.7

1.165

8.5

1.9

16.5

Mean ± SD

102 ± 46

123 ± 46

20.3 ± 7.2

16.4 ± 5.4

0.630 ± 0.225

9.3 ± 2.3

2.4 ± 0.8

18.9 ± 4.9

  1. SD standard deviation